ReviewCureus2026
Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroimmune Interactions in Inflammatory Skin and Intestinal Diseases.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple biologic agents targeting different inflammatory pathways are available for moderate-to-severe plaque psoriasis. While previous network meta-analyses have compared biologics, most were published before the approval of bimekizumab (the newest dual interleukin [IL]-17A/F inhibitor) and lack head-to-head comparisons incorporating this agent alongside other contemporary biologic therapies. We conducted a systematic literature search of PubMed and Clinical Trials to identify phase III randomized controlled trials comparing biologic treatments for moderate-to-severe plaque psoriasis. The primary outcome was achievement of 90% or greater reduction in Psoriasis Area and Severity Index (PASI 90) at week 16. We performed a frequentist random-effects network meta-analysis to estimate odds ratios (OR) with 95% confidence intervals (CI) for all treatment comparisons. From 642 records identified, 11 phase III randomized controlled trials (10 datasets, 6,657 patients) were included, comparing bimekizumab (IL-17A/F inhibitor), secukinumab (IL-17A inhibitor), risankizumab and guselkumab (IL-23p19 inhibitors), adalimumab (tumor necrosis factor-alpha inhibitor), ustekinumab (IL-12/23 inhibitor), and placebo. Compared with placebo, all active treatments showed significant efficacy: bimekizumab (OR 170.04, 95% CI 104.33-277.14), risankizumab (OR 95% CI 59.97-151.74), guselkumab (OR 82.25, 95% CI 51.23-132.03), secukinumab (OR 75.01, 95% CI 45.37-124.02), adalimumab (OR 30.07, 95% CI 19.16-47.18), and ustekinumab (OR 26.68, 95% CI 16.48-43.20). Network heterogeneity was low (I² = 0.0%) for most comparisons. Bimekizumab demonstrated the highest efficacy for achieving PASI 90 at week 16, followed by risankizumab, guselkumab, and secukinumab. All newer biologic agents showed substantial superiority over adalimumab and ustekinumab. These findings can inform treatment selection and guideline development for moderate-to-severe plaque psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.